Internal Medicine, Infectious Disease · Houston, TX
NPI
1033445804
Since 2009
Specialty
Internal Medicine, Infectious Disease
Code 207RI0200X
Group practices
3
Medicare group memberships
Hospitals
1
Hospital affiliations
6560 Fannin St Ste 1540
Houston, TX, 77030
Phone (713) 799-9997
Groups this clinician bills Medicare through
Medicare paid, 2024
$85K
1,091 services
Medicare patients, 2024
190
Average age 66
Drug cost, 2024
$494K
356 prescriptions
Company payments, 2025
$77.7
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Elizabeth R Ramos-Salazar was code 99232 (hospital e&m - subsequent), 658 times for 147 patients. In total Elizabeth R Ramos-Salazar billed 1,091 services in 12 codes, and Medicare paid $85K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-03-09.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99232 Hospital E&M - Subsequent | Facility | 658 | 147 | $62.30 | $41K |
| 99233 Hospital E&M - Subsequent | Facility | 204 | 84 | $94.04 | $19K |
| 99222 Hospital E&M - Initial | Facility | 127 | 107 | $101.71 | $13K |
| 99223 Hospital E&M - Initial | Facility | 52 | 49 | $133.41 | $6,937 |
| 99214 Office E&M - Established | Office | 20 | 17 | $102.56 | $2,051 |
By year: 2022 $100K for 1,421 services; 2023 $82K for 1,068 services; 2024 $85K for 1,091 services.
Medicare prescription drug claims, 2024
In 2024, the drug Elizabeth R Ramos-Salazar prescribed most often to Medicare patients was Zerbaxa (Ceftolozane/Tazobactam), with 43 prescriptions and refills. In total Elizabeth R Ramos-Salazar wrote 356 Medicare prescriptions that cost $494K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Zerbaxa Ceftolozane/Tazobactam | 43 | 43 | Under 11 | $236K |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 29 | 33 | Under 11 | $348 |
| Juluca Dolutegravir/Rilpivirine | 20 | 20 | Under 11 | $68K |
| Ciprofloxacin Hcl Generic | 18 | 18 | Under 11 | $390 |
| Ertapenem Ertapenem Sodium | 17 | 17 | Under 11 | $7,012 |
| Doxycycline Hyclate Generic | 15 | 27 | Under 11 | $774 |
| Daptomycin Generic | 15 | 15 | Under 11 | $12K |
| Isoniazid Generic | 14 | 16 | Under 11 | $81.04 |
| Minocycline Hcl Generic | 14 | 24 | Under 11 | $708 |
| Ethambutol Hcl Generic | 12 | 12 | Under 11 | $169 |
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | 11 | 11 | Under 11 | $48K |
Brand drugs: 103 claims; generic drugs: 253 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Elizabeth R Ramos-Salazar $77.7 ($77.7 in general payments such as food, travel and fees) from 1 company. The largest payer was Abbvie Inc. with $77.7.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 3 | $77.7 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.